Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Imro

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
International Journal of Cancer|May 4, 1999
Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytesM Ferrarini, M A Imro, C Sciorati, et al.
Clinical and Experimental Rheumatology|September 1, 1996
dsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: correlation with clinical disease activityG Filaci, I Grasso, P Contini, et al.
The Journal of Experimental Medicine|March 2, 1999
Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11S Manici, T Sturniolo, M A Imro, et al.
Cancer Research|March 15, 1996
Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitroM P Protti, M A Imro, A A Manfredi, et al.
Oncogene|March 7, 1996
IL2 triggers a tumor progression process in a melanoma cell line MELP derived from a patient whose metastasis increased in size during IL2/INFalpha biotherapyD Han, C Pottin-Clemenceau, M A Imro, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
International Journal of Cancer|May 4, 1999
Blockade of the Fas-triggered intracellular signaling pathway in human melanomas is circumvented by cytotoxic lymphocytesM Ferrarini, M A Imro, C Sciorati, et al.
Clinical and Experimental Rheumatology|September 1, 1996
dsDNA-, nucleohistone- and DNASE I-reactive T lymphocytes in patients affected by systemic lupus erythematosus: correlation with clinical disease activityG Filaci, I Grasso, P Contini, et al.
The Journal of Experimental Medicine|March 2, 1999
Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11S Manici, T Sturniolo, M A Imro, et al.
Cancer Research|March 15, 1996
Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitroM P Protti, M A Imro, A A Manfredi, et al.
Oncogene|March 7, 1996
IL2 triggers a tumor progression process in a melanoma cell line MELP derived from a patient whose metastasis increased in size during IL2/INFalpha biotherapyD Han, C Pottin-Clemenceau, M A Imro, et al.
Pageof 2